Results of Single Center Prospective Study on Delcath’s PHP Therapy Presented at ECIO 2019
April 16, 2019 08:15 ET
|
Delcath Systems, Inc.
NEW YORK, April 16, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Delcath Joins the Ocular Melanoma Community in Recognizing Rare Disease Day
February 28, 2019 10:38 ET
|
Delcath Systems, Inc.
NEW YORK, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Delcath Announces Acceptance of Abstract for Oral Presentation at ECIO 2019
February 08, 2019 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, Feb. 08, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
Delcath Announces 4th Independent Safety Review of Registration Trial Data for Metastatic Ocular Melanoma: Recommended Continuation with no Trial Modification
December 18, 2018 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
CORRECTING and REPLACING – Delcath Expands Rollout of Registration Trial in Metastatic Ocular Melanoma
October 15, 2018 10:57 ET
|
Delcath Systems, Inc.
Seven Cancer Centers in United States Open for Enrollment in Amended Trial NEW YORK, Oct. 15, 2018 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Delcath...
Delcath Expands Rollout of Registration Trial in Metastatic Ocular Melanoma
October 15, 2018 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
Data from Prospective Phase 2 Study Investigating Delcath’s PHP Therapy presented at CIRSE 2018
September 26, 2018 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Data on Delcath’s PHP Therapy presented at CIRSE 2018
September 24, 2018 08:00 ET
|
Delcath Systems, Inc.
NEW YORK, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,...
Delcath Announces 3rd Independent Safety Review of Randomized Trial Data for Metastatic Ocular Melanoma; Recommended Continuation with no Trial Modification
August 23, 2018 11:14 ET
|
Delcath Systems, Inc.
NEW YORK, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
First Patient Enrolled in Delcath Amended Registration Trial in Metastatic Ocular Melanoma
August 21, 2018 08:52 ET
|
Delcath Systems, Inc.
NEW YORK, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...